Outpatient Worsening Heart Failure Predicts Mortality in Patients With ATTR-CM

Outpatient worsening heart failure (HF) may serve as an important clinical marker of disease progression and mortality in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM), according to new findings from the HELIOS-B (NCT04153149) trial.1

The study, published in Journal of the American College of Cardiology, also found that treatment with vutrisiran (Amvuttra; Alnylam Pharmaceuticals) significantly reduced the rate of outpatient HF worsening events over 36 months.|

“Our results indicate that outpatient worsening HF is an early, sensitive indicator of increasing risk of all-cause mortality and CV [cardiovascular] events,” wrote the researchers of the study.